1 In the REIMAGINE 2 trial, the most commonly reported AEs were GI-related, occurring in 405/603 (67.2%) participants in the CagriSema 2.4 mg/2.4 mg group, 326/605 (53.9%) participants in the semaglutide 2.4 mg group, 60/152 (39.5%) participants in the cagrilintide 2.4 mg group, 329/594 (55.4%) participants in the CagriSema 1 mg/1 mg group, 288/608 (47.4%) participants in the semaglutide 1 mg group, and 42/149 (28.2%) participants in the placebo group
Individual results vary significantly based on diet, exercise, baseline weight, and adherence to protocol
Participants on CagriSema achieved a mean body weight reduction of approximately 15.6% from baseline substantially greater than either semaglutide or cagrilintide administered alone
Vitastir has been around awhile and thats why i chose them for my terzepatide order
And unlike most pharmaceuticals, they work with your body's existing biology rather than overriding it
Tumor volumes and body weight were measured every two days and the results were as good as the ones obtained with the commercial antibody Durvalumab (Fig